Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Wellbutrin
|
| gptkbp:affects |
improved energy levels
mood stabilization cardiovascular effects increased risk of seizures potential for dependence |
| gptkbp:brand |
gptkb:Zyban
gptkb:Wellbutrin |
| gptkbp:category |
Category C
|
| gptkbp:class |
norepinephrine-dopamine reuptake inhibitor
aminoketone antidepressant |
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
eating disorders
alcohol use disorder seizure disorder |
| gptkbp:dosage_form |
extended-release tablet
300 mg once daily 150 mg once daily |
| gptkbp:healthcare |
gptkb:2003
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wellbutrin XL
|
| gptkbp:ingredients |
gptkb:bupropion
|
| gptkbp:interacts_with |
antihistamines
antipsychotics opioids monoamine oxidase inhibitors other antidepressants |
| gptkbp:is_atype_of |
N06 A X12
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_used_for |
gptkb:historical_event
anxiety seasonal affective disorder |
| gptkbp:lifespan |
21 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:marketed_as |
gptkb:drug
|
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
anxiety
dizziness headache nausea weight loss insomnia dry mouth sweating tremors agitation |
| gptkbp:social_structure |
C13 H18 Cl N O2
|
| gptkbp:symptoms |
gptkb:historical_event
anxiety fatigue sleep disturbances irritability |